Hot Products
| Catalog No. | Information |
| CFN95260 | Phyllanthusiin C Reference standards. |
| CFN97901 | Phyllostine Phyllostine appears to be their more immediate precursor, since PCMB-treated extracts of J2 converted Phyllostine but not isoepoxydon to these new metabolites. |
| CFN92069 | Phyltetralin Phyltetralin has antihyperuricemic activity. |
| CFN70273 | Physalien Reference standards. |
| CFN92940 | Physalin A Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling, it inhibits androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression. Physalin A induces apoptosis via p53-Noxa-mediated ROS generation, and autophagy plays a protective role against apoptosis through p38-NF-κB survival pathway in A375-S2 cells. |
| CFN92941 | Physalin B Physalin B shows antimalarial, anti-Trypanosoma cruzi, anti-bacterial, anti- leukemia activities, it has the potential to be developed as an effective chemotherapeutic lead compound for the treatment of malignant melanoma, it inhibits androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression. Physalin B exhibits a minimum inhibitory concentration value (MIC) against Mycobacterium tuberculosis H(37)Rv strain of 32 microg/mL. Physalin B also presents antinociceptive properties associated with central. |
| CFN92939 | Physalin D Physalin D shows antimalarial activity; it also exhibits a minimum inhibitory concentration value (MIC) against Mycobacterium tuberculosis H(37)Rv strain of 32 microg/mL. Physalin D displays considerable cytotoxicity against several cancer cell lines. It presents antinociceptive properties associated with central. |
| CFN91811 | Physalin F |
| CFN95104 | Physalin G Physalin G has antinociceptive property. |
| CFN90166 | Physalin L Physalin L shows a distinct fluorescence spot under UV 365 nm with good separation. |
